Ilva Dana Rupenthal Department of Ophthalmology The University of Auckland Biography Publications Institution JoVE Articles Ilva Dana Rupenthal Ilva is currently an Associate Professor and Deputy Head in the Department of Ophthalmology as well as the Director of the Buchanan Ocular Therapeutics Unit, which aims to develop and translate ocular therapeutic related scientific research into the clinical setting. She received a BPharm from the Philipps-University of Marburg, Germany, in 2003 and completed a PhD on ‘Ocular delivery of antisense oligonucleotides’ with the School of Pharmacy and the Department of Ophthalmology, University of Auckland, in 2008. In 2010, Ilva was awarded a prestigious three-year New Zealand Science and Technology Postdoctoral Fellowship to establish an ocular pharmaceutics group within the New Zealand National Eye Centre. In 2013, she then received a prestigious HRC Sir Charles Hercus Research Fellowship to continue her innovative research into stimuli-responsive ocular implants. Dr Rupenthal has received several awards including the 2016 HRC Emerging Researcher Excellence Award, a 2014 University of Auckland Early Career Research Excellence Award and most recently, a Humboldt Research Fellowship for Experienced Researchers. Publications Ocular Distribution of Papaverine Using Non-aqueous Vehicles AAPS PharmSciTech. May, 2021 | Pubmed ID: 34031787 Gelatine-based Drug-eluting Bandage Contact Lenses: Effect of PEGDA Concentration and Manufacturing Technique International Journal of Pharmaceutics. Apr, 2021 | Pubmed ID: 33676990 Effect of Therapeutic UVC on Corneal DNA: Safety Assessment for Potential Keratitis Treatment The Ocular Surface. Apr, 2021 | Pubmed ID: 33610742 Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases International Journal of Molecular Sciences. Feb, 2021 | Pubmed ID: 33578721 Formulation Considerations for the Management of Dry Eye Disease Pharmaceutics. Feb, 2021 | Pubmed ID: 33546193 Connexin43 Hemichannel Block Inhibits NLRP3 Inflammasome Activation in a Human Retinal Explant Model of Diabetic Retinopathy Experimental Eye Research. 01, 2021 | Pubmed ID: 33285185 The Influence of Hyperglycemia on the Safety of Ultrasound in Retinal Pigment Epithelial Cells Cell Biology International. Mar, 2021 | Pubmed ID: 33049086 Micro-interaction of Mucin Tear Film Interface with Particles: The Inconsistency of Pharmacodynamics and Precorneal Retention of Ion-exchange, Functionalized, Mt-embedded Nano- and Microparticles Colloids and Surfaces. B, Biointerfaces. Jan, 2021 | Pubmed ID: 33010720 Connexin Therapeutics: Blocking Connexin Hemichannel Pores is Distinct from Blocking Pannexin Channels or Gap Junctions Neural Regeneration Research. Mar, 2021 | Pubmed ID: 32985469 Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy International Journal of Molecular Sciences. Dec, 2020 | Pubmed ID: 33396676 Characterization of Zinc Oxide Nanoparticle Cross-Linked Collagen Hydrogels Gels (Basel, Switzerland). Oct, 2020 | Pubmed ID: 33105715 Incorporation of Ion Exchange Functionalized-montmorillonite into Solid Lipid Nanoparticles with Low Irritation Enhances Drug Bioavailability for Glaucoma Treatment Drug Delivery. Dec, 2020 | Pubmed ID: 32347126 Xentry-Gap19 Inhibits Connexin43 Hemichannel Opening Especially During Hypoxic Injury Drug Delivery and Translational Research. 06, 2020 | Pubmed ID: 32318976 Relationship Between Rheological Properties and Transverse Relaxation Time (T2) of Artificial and Porcine Vitreous Humour Experimental Eye Research. 05, 2020 | Pubmed ID: 32194065 Validation of Hyaluronic Acid-agar-based Hydrogels As Vitreous Humor Mimetics for in Vitro Drug and Particle Migration Evaluations European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. Mar, 2020 | Pubmed ID: 31981693 Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 01, 2020 | Pubmed ID: 31637594 Connexin43 Hemichannel Block Protects Against Retinal Pigment Epithelial Cell Barrier Breakdown Acta Diabetologica. Jan, 2020 | Pubmed ID: 31030263 Targeting Connexin Hemichannels to Control the Inflammasome: the Correlation Between Connexin43 and NLRP3 Expression in Chronic Eye Disease Expert Opinion on Therapeutic Targets. 10, 2019 | Pubmed ID: 31554417 Ocular Drugs and Drug Delivery Systems - Current Trends and Future Perspectives Drug Discovery Today. 08, 2019 | Pubmed ID: 31330186 Corrigendum to "Overcoming Ocular Drug Delivery Barriers Through the Use of Physical Forces" [Advanced Drug Delivery Reviews 126 (2018) 96-112] Advanced Drug Delivery Reviews. Jan, 2019 | Pubmed ID: 31133328 Depot Formulations to Sustain Periocular Drug Delivery to the Posterior Eye Segment Drug Discovery Today. 08, 2019 | Pubmed ID: 30930148 Ex Vivo Evaluation of the Stability, Safety and Antibacterial Efficacy of an Extemporaneous Povidone-iodine Preparation for Ophthalmic Applications Clinical & Experimental Optometry. 11, 2019 | Pubmed ID: 30924199 Preclinical Studies Evaluating the Effect of Semifluorinated Alkanes on Ocular Surface and Tear Fluid Dynamics The Ocular Surface. 04, 2019 | Pubmed ID: 30831252 Connexin43 Hemichannels: A Potential Drug Target for the Treatment of Diabetic Retinopathy Drug Discovery Today. 08, 2019 | Pubmed ID: 30690195 Ultrasound-responsive Nanobubbles for Enhanced Intravitreal Drug Migration: An Ex Vivo Evaluation European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. Mar, 2019 | Pubmed ID: 30660691 Connexin43 Hemichannel Block Protects Against the Development of Diabetic Retinopathy Signs in a Mouse Model of the Disease Journal of Molecular Medicine (Berlin, Germany). 02, 2019 | Pubmed ID: 30535867 Evaluation of 2 Ex Vivo Bovine Cornea Storage Protocols for Drug Delivery Applications Ophthalmic Research. Month, 2019 | Pubmed ID: 30466090 Intravitreal Pro-inflammatory Cytokines in Non-obese Diabetic Mice: Modelling Signs of Diabetic Retinopathy PloS One. Month, 2018 | Pubmed ID: 30133488 Intracellular Oligonucleotide Delivery Using the Cell Penetrating Peptide Xentry Scientific Reports. 07, 2018 | Pubmed ID: 30050146 Sustained Connexin43 Mimetic Peptide Release From Loaded Nanoparticles Reduces Retinal and Choroidal Photodamage Investigative Ophthalmology & Visual Science. 07, 2018 | Pubmed ID: 30029255 Drug Delivery to the Lens for the Management of Cataracts Advanced Drug Delivery Reviews. 02, 2018 | Pubmed ID: 29604375 Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery in the Treatment of Retinal Ischaemia Biomaterials. 06, 2018 | Pubmed ID: 29597134 Micelle Directed Chemical Polymerization of Polypyrrole Particles for the Electrically Triggered Release of Dexamethasone Base and Dexamethasone Phosphate International Journal of Pharmaceutics. May, 2018 | Pubmed ID: 29581065 Effects of Enzymatic Degradation on Dynamic Mechanical Properties of the Vitreous and Intravitreal Nanoparticle Mobility European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. Jun, 2018 | Pubmed ID: 29574081 Semifluorinated Alkane Based Systems for Enhanced Corneal Penetration of Poorly Soluble Drugs International Journal of Pharmaceutics. Mar, 2018 | Pubmed ID: 29339249 Erratum to "Ultrasound-mediated Nanoparticle Delivery Across Ex Vivo Bovine Retina After Intravitreal Injection" [Eur. J. Pharm. Biopharm. 119 (2017) 125-136] European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. 02, 2018 | Pubmed ID: 29222046 The Inflammasome Pathway is Amplified and Perpetuated in an Autocrine Manner Through Connexin43 Hemichannel Mediated ATP Release Biochimica Et Biophysica Acta. General Subjects. Mar, 2018 | Pubmed ID: 29158134 Overcoming Ocular Drug Delivery Barriers Through the Use of Physical Forces Advanced Drug Delivery Reviews. 02, 2018 | Pubmed ID: 28916492 Medicated Ocular Bandages and Corneal Health: Potential Excipients and Active Pharmaceutical Ingredients Pharmaceutical Development and Technology. Mar, 2018 | Pubmed ID: 28875742 Phase Transition of a Microemulsion Upon Addition of Cyclodextrin - Applications in Drug Delivery Pharmaceutical Development and Technology. Feb, 2018 | Pubmed ID: 28828910 Nanocarrier Mediated Retinal Drug Delivery: Overcoming Ocular Barriers to Treat Posterior Eye Diseases Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology. 03, 2018 | Pubmed ID: 28425224 PLGA Nanoparticles for Intravitreal Peptide Delivery: Statistical Optimization, Characterization and Toxicity Evaluation Pharmaceutical Development and Technology. Apr, 2018 | Pubmed ID: 27670289 Development of a Novel Stability Indicating RP-HPLC Method for Quantification of Connexin43 Mimetic Peptide and Determination of Its Degradation Kinetics in Biological Fluids Journal of Pharmaceutical Analysis. Dec, 2017 | Pubmed ID: 29404061 Formulation Development and Evaluation of the Therapeutic Efficacy of Brinzolamide Containing Nanoemulsions Iranian Journal of Pharmaceutical Research : IJPR. Month, 2017 | Pubmed ID: 29201076 Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas International Journal of Molecular Sciences. Nov, 2017 | Pubmed ID: 29186067 Drug-device Combination Approaches for Delivery to the Eye Current Opinion in Pharmacology. 10, 2017 | Pubmed ID: 28843865 Ultrasound-mediated Nanoparticle Delivery Across Ex Vivo Bovine Retina After Intravitreal Injection European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. Oct, 2017 | Pubmed ID: 28602870 Nanoparticle-loaded Biodegradable Light-responsive in Situ Forming Injectable Implants for Effective Peptide Delivery to the Posterior Segment of the Eye Medical Hypotheses. Jun, 2017 | Pubmed ID: 28571808 Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. Oct, 2017 | Pubmed ID: 28560708 Polymeric Micelles for Ocular Drug Delivery: From Structural Frameworks to Recent Preclinical Studies Journal of Controlled Release : Official Journal of the Controlled Release Society. 02, 2017 | Pubmed ID: 28087407 Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina Molecular Pharmaceutics. 02, 2017 | Pubmed ID: 27997199 Ocular Drug Delivery-eye on Innovation Drug Delivery and Translational Research. 12, 2016 | Pubmed ID: 27766597 Ex Vivo Investigation of Ocular Tissue Distribution Following Intravitreal Administration of Connexin43 Mimetic Peptide Using the Microdialysis Technique and LC-MS/MS Drug Delivery and Translational Research. 12, 2016 | Pubmed ID: 27371395 Modern Approaches to the Ocular Delivery of Cyclosporine A Drug Discovery Today. 06, 2016 | Pubmed ID: 27080149 Nanoparticle Cross-linked Collagen Shields for Sustained Delivery of Pilocarpine Hydrochloride International Journal of Pharmaceutics. Mar, 2016 | Pubmed ID: 26828672 In Vitro and Ex Vivo Corneal Penetration and Absorption Models Drug Delivery and Translational Research. 12, 2016 | Pubmed ID: 26762419 Ex Vivo and In Vivo Evaluation of Chitosan Coated Nanostructured Lipid Carriers for Ocular Delivery of Acyclovir Current Drug Delivery. Month, 2016 | Pubmed ID: 26568139 Connexin43 in Retinal Injury and Disease Progress in Retinal and Eye Research. Mar, 2016 | Pubmed ID: 26432657 Ocular Delivery Systems for Topical Application of Anti-infective Agents Drug Development and Industrial Pharmacy. Jan, 2016 | Pubmed ID: 26325119 Intravitreal Injection of Lipoamino Acid-modified Connexin43 Mimetic Peptide Enhances Neuroprotection After Retinal Ischemia Drug Delivery and Translational Research. Oct, 2015 | Pubmed ID: 26238242 Neuroprotection in the Treatment of Glaucoma--A Focus on Connexin43 Gap Junction Channel Blockers European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. Sep, 2015 | Pubmed ID: 25676338 Sustained Intravitreal Delivery of Connexin43 Mimetic Peptide by Poly(D,L-lactide-co-glycolide) Acid Micro- and Nanoparticles--Closing the Gap in Retinal Ischaemia European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. Sep, 2015 | Pubmed ID: 25497487 Implants for Drug Delivery to the Posterior Segment of the Eye: a Focus on Stimuli-responsive and Tunable Release Systems Journal of Controlled Release : Official Journal of the Controlled Release Society. Dec, 2014 | Pubmed ID: 25307997 Dendrimers for Gene Delivery--a Potential Approach for Ocular Therapy? The Journal of Pharmacy and Pharmacology. Apr, 2014 | Pubmed ID: 24635556 Cytotoxicity and Vitreous Stability of Chemically Modified Connexin43 Mimetic Peptides for the Treatment of Optic Neuropathy Journal of Pharmaceutical Sciences. Jul, 2013 | Pubmed ID: 23696181 Injectable Implants for the Sustained Release of Protein and Peptide Drugs Drug Discovery Today. Apr, 2013 | Pubmed ID: 23410799 Synergistic Effect of Chemical Penetration Enhancer and Iontophoresis on Transappendageal Transport of Oligodeoxynucleotides International Journal of Pharmaceutics. Jan, 2013 | Pubmed ID: 23099122 Improved Corneal Wound Healing Through Modulation of Gap Junction Communication Using Connexin43-specific Antisense Oligodeoxynucleotides Investigative Ophthalmology & Visual Science. Mar, 2012 | Pubmed ID: 22247467 Ion-activated in Situ Gelling Systems for Antisense Oligodeoxynucleotide Delivery to the Ocular Surface Molecular Pharmaceutics. Dec, 2011 | Pubmed ID: 21985532 In Vitro Release Characteristics and Cellular Uptake of Poly(D,L-lactic-co-glycolic Acid) Nanoparticles for Topical Delivery of Antisense Oligodeoxynucleotides Drug Delivery. Sep-Oct, 2011 | Pubmed ID: 21696294 Comparison of Ion-activated in Situ Gelling Systems for Ocular Drug Delivery. Part 2: Precorneal Retention and in Vivo Pharmacodynamic Study International Journal of Pharmaceutics. Jun, 2011 | Pubmed ID: 21453763 Comparison of Ion-activated in Situ Gelling Systems for Ocular Drug Delivery. Part 1: Physicochemical Characterisation and in Vitro Release International Journal of Pharmaceutics. Jun, 2011 | Pubmed ID: 21453762 Ex Vivo Evaluation of the Influence of PH on the Ophthalmic Safety, Antibacterial Efficacy and Storage Stability of Povidone-iodine Clinical & Experimental Optometry. Month, | Pubmed ID: 32495387 Topical Semifluorinated Alkane-based Azithromycin Suspension for the Management of Ocular Infections European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. Month, | Pubmed ID: 31195132 Randomised Masked Trial of the Clinical Safety and Tolerability of MGO Manuka Honey Eye Cream for the Management of Blepharitis BMJ Open Ophthalmology. Month, | Pubmed ID: 29354710 Preclinical Development of MGO Manuka Honey Microemulsion for Blepharitis Management BMJ Open Ophthalmology. Month, | Pubmed ID: 29354709 Characterization of a Novel Human Organotypic Retinal Culture Technique Charisse Y. J. Kuo*1, Henry H. Louie1, Ilva D. Rupenthal1, Odunayo O. Mugisho*1 1Buchanan Ocular Therapeutics Unit, Department of Ophthalmology and the New Zealand National Eye Centre, University of Auckland JoVE 62046 医学
Characterization of a Novel Human Organotypic Retinal Culture Technique Charisse Y. J. Kuo*1, Henry H. Louie1, Ilva D. Rupenthal1, Odunayo O. Mugisho*1 1Buchanan Ocular Therapeutics Unit, Department of Ophthalmology and the New Zealand National Eye Centre, University of Auckland JoVE 62046 医学